TY - JOUR T1 - Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study JF - Anticancer Research JO - Anticancer Res SP - 957 LP - 964 DO - 10.21873/anticanres.14029 VL - 40 IS - 2 AU - SHINICHIRO OKAUCHI AU - TAKESHI NUMATA AU - TAKESHI NAWA AU - HIDEO ICHIMURA AU - TAKEFUMI SAITO AU - KENJI HAYASHIHARA AU - HIDEYASU YAMADA AU - HIROAKI SATOH AU - TAKESHI ENDO AU - YOSHIHISA INAGE AU - TAKAYUKI KABURAGI AU - MORIYUKI KIYOSHIMA AU - YUTAKA YAMADA AU - TOMOHIRO TAMURA AU - KAZUHITO SAITO AU - MASAHARU INAGAKI AU - NOBUYUKI HIZAWA AU - YUKIO SATO AU - TOSHIHIRO SHIOZAWA AU - IKUO SEKINE AU - HIROICHI ISHIKAWA AU - KOICHI KURIHIMA AU - MITSUAKI SAKAI AU - KOICHI KAMIYAMA AU - MASAKI KIMURA AU - NORIHIRO KIKUCHI AU - HIROYUKI NAKAMURA AU - KINYA FURUKAWA AU - TAKAHIDE KODAMA AU - KUNIHIKO MIYAZAKI AU - TAKAAKI YAMASHITA AU - SHIGEN HAYASHI AU - YASUNORI FUNAYAMA AU - AKIHIRO NOMURA Y1 - 2020/02/01 UR - http://ar.iiarjournals.org/content/40/2/957.abstract N2 - Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice. ER -